UCB’s Fintepla has been approved to treat seizures associated with two epilepsy disorders and now has posted data that could ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

A potential $4 billion licensing deal with Vor Bio triggered a slide in RemeGen's stock price. Otsuka obtained a BCMAXCD3 ...

For $45 million upfront, Vor Bio is gaining ex-China rights to RemeGen’s telitacicept, a first-in-class recombinant ...

Merck KGaA executive Renee Connolly and Gen Z recording artist Lola Young joined Havas Health and Creative Networks CEO Donna ...

Robert F. Kennedy Jr.’s revamped Advisory Committee on Immunization Practices has struck its first blow against established ...

The CDC’s Advisory Committee on Immunization Practices (ACIP) has blessed Merck’s new respiratory syncytial virus (RSV) shot ...

The medtech this week launched a podcast called “Decoded,” in which founder and CEO Jurgi Camblong, Ph.D., will host expert ...

After blueprinting an injectables facility in North Carolina in 2020, it didn’t take long for Eli Lilly to draw up designs ...

After over a decade spent building Incyte up into a competitive commercial drugmaker, the company’s longtime CEO Hervé ...

Restricted availability under an FDA-mandated drug safety program has limited the reach of CAR-T cell therapies for certain blood cancers—until now. | The FDA has removed the REMS requirements for ...